Here, we build on these initial reports by performing a comprehensive genomic analysis on 5 patients with DMGs lacking the H3K27M mutation but with a loss of H3K27me3, and up-regulation of EZHIP. We show that these tumours can be divided into distinct subgroups based on their genomic profile and define their clinical outcome. This evidence concerns the gene EZHIP and neoplasm.